These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 33273347

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. RE-CIRCUIT: uninterrupted anticoagulation with dabigatran to cover left atrial ablation procedures.
    Camm AJ.
    Cardiovasc Res; 2018 Oct 01; 114(12):e89-e90. PubMed ID: 31346598
    [No Abstract] [Full Text] [Related]

  • 23. Dabigatran Reversal With Idarucizumab Preceding Thrombolysis in an Octogenarian Patient with Chronic Kidney Disease and Acute Stroke: A Case Report.
    Laxamana LC, Co COC, Yu JRT, Mojica CV, Iboleon-Dy MAM, Domingo AMC, Ilano KCS, Macrohon-Valdez MCZ.
    Clin Ther; 2020 Sep 01; 42(9):1840-1845. PubMed ID: 32778345
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Palmoplantar pustular eruption due to dabigatran.
    Schleichert R, Goldner R, Dickfeld T.
    Cutis; 2016 May 01; 97(5):E10-1. PubMed ID: 27274551
    [No Abstract] [Full Text] [Related]

  • 26. The Risk of Acute Kidney Injury with Oral Anticoagulants in Elderly Adults with Atrial Fibrillation.
    Harel Z, McArthur E, Jeyakumar N, Sood MM, Garg AX, Silver SA, Dorian P, Blum D, Beaubien-Souligny W, Yan AT, Badve SV, Smyth B, Jun M, Jandoc R, Kitchlu A, Wald R.
    Clin J Am Soc Nephrol; 2021 Oct 01; 16(10):1470-1479. PubMed ID: 34407990
    [Abstract] [Full Text] [Related]

  • 27. Persistent life-threatening hemorrhage after administration of idarucizumab.
    Alhashem HM, Avendano C, Hayes BD, Winters ME.
    Am J Emerg Med; 2017 Jan 01; 35(1):193.e3-193.e5. PubMed ID: 27439386
    [No Abstract] [Full Text] [Related]

  • 28. Dabigatran and vitamin K antagonists' use in naïve patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records.
    Vlacho B, Giner-Soriano M, Zabaleta-Del-Olmo E, Roso-Llorach A, García-Sangenís A, Morros-Pedrós R.
    Eur J Clin Pharmacol; 2017 Oct 01; 73(10):1323-1330. PubMed ID: 28725983
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Bleeding-related hospital admissions and 30-day readmissions in patients with non-valvular atrial fibrillation treated with dabigatran versus warfarin.
    Lau WCY, Li X, Wong ICK, Man KKC, Lip GYH, Leung WK, Siu CW, Chan EW.
    J Thromb Haemost; 2017 Oct 01; 15(10):1923-1933. PubMed ID: 28748652
    [Abstract] [Full Text] [Related]

  • 31. The assessment of anticoagulant activity to predict bleeding outcome in atrial fibrillation patients receiving dabigatran etexilate.
    Chang YT, Hu YF, Liao JN, Chern CM, Lin YJ, Chang SL, Wu CH, Sung SH, Wang KL, Lu TM, Chao TF, Lo LW, Hsu LC, Chung CP, Chang PM, Hsu WH, Chiou CW, Chen SA.
    Blood Coagul Fibrinolysis; 2016 Jun 01; 27(4):389-95. PubMed ID: 26991859
    [Abstract] [Full Text] [Related]

  • 32. Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin.
    Chan YH, Yeh YH, See LC, Wang CL, Chang SH, Lee HF, Wu LS, Tu HT, Kuo CT.
    J Am Coll Cardiol; 2016 Nov 29; 68(21):2272-2283. PubMed ID: 27884245
    [Abstract] [Full Text] [Related]

  • 33. [Nosebleed in new oral anticoagulant treatment - what should be done?].
    Stiefelhagen P.
    MMW Fortschr Med; 2015 Sep 10; 157(15):25. PubMed ID: 26349711
    [No Abstract] [Full Text] [Related]

  • 34. Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
    Rosenberg L, Gerstrøm G, Nybo M.
    Basic Clin Pharmacol Toxicol; 2017 Apr 10; 120(4):407-410. PubMed ID: 27797449
    [Abstract] [Full Text] [Related]

  • 35. Dabigatran plasma concentration indicated the risk of patients with non-valvular atrial fibrillation.
    Zhu Z, Shen Z, Shi A, Su C, Mao J, Tao H, Xu F, Hu Z, Pan J.
    Heart Vessels; 2022 May 10; 37(5):821-827. PubMed ID: 34694442
    [Abstract] [Full Text] [Related]

  • 36. Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.
    Agosti S, Casalino L, Rocci E, Zaccone G, Rota E.
    J Med Case Rep; 2017 Aug 15; 11(1):224. PubMed ID: 28806993
    [Abstract] [Full Text] [Related]

  • 37. Emergency abdominal surgery in a patient anticoagulated with dabigatran.
    DeMuro JP.
    Ulus Travma Acil Cerrahi Derg; 2013 Sep 15; 19(5):469-71. PubMed ID: 24214790
    [Abstract] [Full Text] [Related]

  • 38. Dabigatran-induced nephropathy and its successful treatment with Idarucizumab - case report and literature review.
    Awesat J, Sagy I, Haviv YS, Rabinovich A, Jotkowitz A, Shleyfer E, Barski L.
    Thromb Res; 2018 Sep 15; 169():120-122. PubMed ID: 30032039
    [Abstract] [Full Text] [Related]

  • 39. Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience.
    Mumoli N, Mastroiacovo D, Tamborini-Permunian E, Vitale J, Giorgi-Pierfranceschi M, Cei M, Dentali F.
    J Cardiovasc Med (Hagerstown); 2017 Jul 15; 18(7):467-477. PubMed ID: 28509761
    [Abstract] [Full Text] [Related]

  • 40. Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study.
    Pallisgaard JL, Lindhardt TB, Hansen ML, Schjerning AM, Olesen JB, Staerk L, Torp-Pedersen C, Gislason GH.
    PLoS One; 2015 Jul 15; 10(10):e0141377. PubMed ID: 26513589
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.